D. E. Shaw & Co., Inc. Igm Biosciences, Inc. Call Options Transaction History
D. E. Shaw & Co., Inc.
- $107 Billion
- Q3 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding IGMS
# of Institutions
81Shares Held
20.7MCall Options Held
68KPut Options Held
52.2K-
Baker Bros. Advisors LP New York, NY4.09MShares$38.7 Million0.72% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD4.01MShares$38 Million0.01% of portfolio
-
Siren, L.L.C. New York, NY3.33MShares$31.5 Million2.75% of portfolio
-
Redmile Group, LLC San Francisco, CA3.07MShares$29.1 Million3.32% of portfolio
-
Goldman Sachs Group Inc New York, NY1.26MShares$11.9 Million0.0% of portfolio
About IGM Biosciences, Inc.
- Ticker IGMS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 28,969,000
- Market Cap $274M
- Description
- IGM Biosciences, Inc., a biotechnology company, develops Immunoglobulin M (IgM) antibodies for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. The company's lead product candidate is IGM-2323, a bispecific IgM antibody that is in Phase 2 clinical trials to treat patients with relapsed/refractory B cell Non...